Everest Medicines Limited (FRA:6HN)
4.480
+0.360 (8.74%)
At close: Jan 23, 2026
Everest Medicines Revenue
Everest Medicines had revenue of 446.12M CNY in the half year ending June 30, 2025, with 4,915.44% growth. This brings the company's revenue in the last twelve months to 851.28M, up 103.39% year-over-year. In the year 2024, Everest Medicines had annual revenue of 706.68M with 461.16% growth.
Revenue (ttm)
851.28M CNY
Revenue Growth
+103.39%
P/S Ratio
14.66
Revenue / Employee
1.18M CNY
Employees
722
Market Cap
1.48B EUR
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 706.68M | 580.75M | 461.16% |
| Dec 31, 2023 | 125.93M | 113.14M | 884.46% |
| Dec 31, 2022 | 12.79M | 12.74M | 23,588.89% |
| Dec 31, 2021 | 54.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mainova AG | 3.89B |
| Gelsenwasser AG | 3.36B |
| Paul Hartmann AG | 2.44B |
| Lechwerke AG | 1.06B |
| tonies SE | 510.38M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |